摘要
目的比较携带小鼠IL12基因的增殖型腺病毒(CNHK200mIL12)和非增殖型腺病毒(AdvmIL12)对IL12基因的表达以及对肝癌细胞的杀伤能力。方法通过MTT以及病毒增殖实验,评估E1B55000缺陷的增殖型腺病毒CNHK200mIL12和ONYX015(dl1520),以及非增殖型腺病毒AdvmIL12对人正常肝细胞株LO2、人肝癌细胞株HepG2和Hep3B的杀伤能力。采用蛋白质印迹分析和ELISA法,检测CNHK200mIL12和AdvmIL12感染HepG2和Hep3B细胞后,小鼠IL12基因的表达情况。结果CNHK200mIL12感染HepG2和Hep3B细胞后大量增殖,在感染后96h时检测,分别增殖3160倍和630倍,在极低的MOI(空斑形成单位/细胞)值和极短的时间内(HepG2细胞MOI=0.2,第4天;Hep3B细胞MOI=0.005,第2天),可大量杀伤肿瘤细胞,而对LO2细胞无明显杀伤。CNHK200mIL12和AdvmIL12感染HepG2细胞后,其IL12基因表达量,前者是后者的101倍;感染Hep3B细胞后,前者是后者的20倍。结论增殖型腺病毒载体对肿瘤细胞的杀伤能力和目的基因的表达,明显优于传统的非增殖型腺病毒载体,应用前景广阔。
Objective To evaluate the therapeutic effect and the expression level of a tumor specific replication competent adenovirus and a replication defective adenovirus expression mouse recombinant IL 12 (mIL 12) gene on hepatocellular carcinoma (HCC) in vitro. Methods The cytotoxicity of replication competent adenovirus with E1B 55 000 attenuated CNHK200 mIL12 and ONYX 015 (dl1520), and replication defective adenovirus Adv mIL12 were evaluated by MTT and replication assay in two HCC cell lines (HepG2 and Hep3B) and human normal hepatocyte line (LO2). Western blot and ELISA were used to determine the expression level of mIL 12. Results CNHK200 mIL12 replicated in HepG2 and Hep3B with an increase of 3,160 fold and 630 fold respectively in 96 h post infection. CNHK200 mIL12 could kill HepG2 and Hep3B cells at a very low MOI (Multiplicity of Infection) and in short time course(HepG2:MOI=0.2, on day 4; Hep3B:MOI=0.005, on day 2), while it had no significant effect on LO2. Furthermore, the expressing level of mIL 12 in CNHK200 mIL12 treated HCC cell lines was much higher than that in Adv mIL12 treated one(HepG2 101 fold,Hep3B 20 fold respectively). Conclusion Replication competent adenovirus is more effective than replication defective adenovirus in both cytotoxicity and efficiency of gene transfer in HCC, and holds great promise in the area of HCC therapy.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2004年第10期581-584,共4页
Chinese Journal of Oncology
基金
国家863高技术研究发展计划基金重点资助项目(2001AA217031)
国家自然科学基金国际合作项目(30120160824)
